1,011 reports of this reaction
6.5% of all ROFLUMILAST reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for ROFLUMILAST, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,011 FDA adverse event reports linking ROFLUMILAST to DYSPNOEA. This represents approximately 6.5% of all 15,466 adverse event reports for this drug.
Patients taking ROFLUMILAST who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among ROFLUMILAST users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for ROFLUMILAST:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,011 FDA reports for ROFLUMILAST. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 6.5% of all adverse event reports for ROFLUMILAST, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking ROFLUMILAST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.